PROSTATE HEALTH TINCTURE
Natural health product licensed in Canada
- Other names
- MOLALIFE PROSTATE HEALTH TINCTURE, MOLESCI & MATESCI SAW PALMETTO PROSTATE HEALTH TINCTURE, SAW PALMETTO TINCTURE
- Licence holder
- Molesci & Matesci Inc.
- NPN or DIN-HM
- 80062763
- Status
- Active licence
- Licence date
- 16 July 2015
- Revision date
- 4 August 2015
- Form
- Teinture
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Serenoa repens Source : Serenoa repens - fruit Extract : Matériel brut sec Extraction ratio : 1:2 Dry plant equivalent : 500 milligramme Potency : 70 Pour cent fatty acids | 1,000 milligramme | Not calculated |
Non-medicinal ingredients
Alcool éthylique, Eau purifiée
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | Not specified | minimum: 1 millilitre ; maximum: 2 millilitre | 2 Tous les jours |
Uses authorised in Canada
Used in Herbal Medicine to help relieve the urologic symptoms (like weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasi.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner if symptoms persist. Consult a health care practitioner if symptoms worsen. Consult a health care practitioner prior to use to exclude a diagnosis of prostate cancer.
Source
Official Health Canada record, licence 80062763
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2015. Photograph the packaging to check whether it has changed. Photograph the packaging